Trials / No Longer Available
No Longer AvailableNCT04907175
Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Hope Biosciences Research Foundation · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.
Detailed description
This Individual Patient Expanded Access IND has been created per the request of a 65-year-old woman diagnosed with Systemic Lupus Erythematosus (SLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HB-adMSCs | Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year. |
Timeline
- First posted
- 2021-05-28
- Last updated
- 2025-09-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04907175. Inclusion in this directory is not an endorsement.